dc.contributor.author |
Pastor, Lucía |
dc.contributor.author |
Casellas, Aina |
dc.contributor.author |
Rupérez, María |
dc.contributor.author |
Carrillo, Jorge |
dc.contributor.author |
Maculuve, Sónia Amós |
dc.contributor.author |
Jairoce, Chenjerai |
dc.contributor.author |
Paredes, Roger |
dc.contributor.author |
Blanco, Julià |
dc.contributor.author |
Naniche, Denise |
dc.date |
2017-11-10T13:43:07Z |
dc.date |
2017-11-10T13:43:07Z |
dc.date |
2017-10-30 |
dc.date |
2017-11-01T19:00:10Z |
dc.identifier.citation |
1058-4838 |
dc.identifier.uri |
http://hdl.handle.net/2445/117626 |
dc.format |
6 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Oxford University Press |
dc.relation |
Reproducció del document publicat a:
http://dx.doi.org/10.1093/cid/cix600 |
dc.relation |
Clinical Infectious Diseases, 2017, vol.65 , num.10 , p. 1670-1675 |
dc.relation |
http://dx.doi.org/10.1093/cid/cix600 |
dc.rights |
cc by (c) Pastor et al., 2017 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Citoquines |
dc.subject |
Immunitat cel·lular |
dc.subject |
Cytokines |
dc.subject |
Cellular immunity |
dc.title |
Interferon-gamma-Inducible Protein 10 (IP-10) as a Screening
Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in
Resource-Limited Settings |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
Background: Achieving effective antiretroviral treatment (ART)
monitoring is a key determinant to ensure viral suppression and
reach the UNAIDS 90-90-90 targets. The gold standard for
detecting virological failure is plasma human immunodeficiency
virus (HIV) RNA (viral load [VL]) testing; however, its
availability is very limited in low-income countries due to cost
and operational constraints. Methods: HIV-1-infected adults on
first-line ART attending routine visits at the Manhica District
Hospital, Mozambique, were previously evaluated for virologic
failure. Plasma levels of interferon-gamma-inducible protein 10
(IP-10) were quantified by enzyme-linked immunosorbent assay.
Logistic regression was used to build an IP-10-based model able
to identify individuals with VL >150 copies/mL. From the 316
individuals analyzed, 253 (80%) were used for model training and
63 (20%) for validation. Receiver operating characteristic
curves were employed to evaluate model prediction. Results: From
the individuals included in the training set, 34% had detectable
VL. Mean age was 41 years, 70% were females, and median time on
ART was 3.4 years. IP-10 levels were significantly higher in
subjects with detectable VL (108.2 pg/mL) as compared to those
with undetectable VL (38.0 pg/mL) (P < .0001, U test). IP-10
univariate model demonstrated high classification performance
(area under the curve = 0.85 [95% confidence interval {CI},
.80-.90]). Using a cutoff value of IP-10 >/=44.2 pg/mL, the
model identified detectable VL with 91.9% sensitivity (95% CI,
83.9%-96.7%) and 59.9% specificity (95% CI, 52.0%-67.4%), values
confirmed in the validation set. Conclusions: IP-10 is an
accurate biomarker to screen individuals on ART for detectable
viremia. Further studies should evaluate the benefits of IP-10
as a triage approach to monitor ART in resource-limited
settings. |